Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Clinical Study on the Safety and Efficacy of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

NCT03690310 is registered in ClinicalTrials.gov with Allife Medical Science and Technology Co., Ltd. as lead sponsor.

NCT NCT03690310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03690310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Clinical Study on the Safety and Efficacy of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Lead sponsor
Allife Medical Science and Technology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
March 31, 2019
Completion date
November 30, 2021
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b-cell lymphoma